A major international Phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab—a ...

Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains? In total, 1,018 patients completed induction treatment and were randomly assigned to rituximab maintenance (n = 505) or ...

Chronic lymphocytic leukemia (CLL) may not show physical symptoms until it progresses, at which point symptoms such as weight loss, fatigue, and night sweats may appear. The speed of CLL progression ...

Here, we aim to review the patterns of response and progression to immunotherapy, especially to immune checkpoint inhibitors. Firstly, we describe the radiographic criteria used to assess response to ...